Clinical Trial Update: Radiotherapy Plus Anti-PD-1 Versus Anti-PD-1 Alone in ypTanyN⁺M0 NSCLC [Phase 2]

View source ↗

Summary

This is a Phase 2 trial comparing radiotherapy plus a PD-1 inhibitor versus PD-1 inhibitor alone in postoperative ypTanyN+M0 non-small cell lung cancer; the stu…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• PD-1 inhibitor

Snippet

Sponsor: Shanghai Zhongshan Hospital | Conditions: NSCLC (Advanced Non-small Cell Lung Cancer), Post Surgical | Phase 2 | Status: NOT_YET_RECRUITING